Suppr超能文献

评估产毒阳性作为沙特阿拉伯抗菌药物管理患者结局指标的情况。

An evaluation of toxigenic positivity as a patient outcome metric of antimicrobial stewardship in Saudi Arabia.

作者信息

Okeahialam Christopher A, Rabaan Ali A, Bolhuis Albert

机构信息

Infection Prevention and Control, Fraser Health Authority, Canada.

Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Saudi Arabia.

出版信息

J Infect Prev. 2021 Sep;22(5):231-236. doi: 10.1177/17571774211012780. Epub 2021 Jun 22.

Abstract

BACKGROUND

Antimicrobial stewardship has been associated with a reduction in the incidence of healthcare-associated infection (HA-CDI). However, CDI remains under-recognised in many low and middle-income countries where clinical and surveillance resources required to identify HA-CDI are often lacking. The rate of toxigenic stool positivity in the stool of hospitalised patients may offer an alternative metric for these settings, but its utility remains largely untested.

AIM/OBJECTIVE: To examine the impact of antimicrobial stewardship on the rate of toxigenic positivity among hospitalised patients presenting with diarrhea.

METHODS

A 12-year retrospective review of laboratory data was conducted to compare the rates of toxigenic in diarrhoea stool of patients in a hospital in Saudi Arabia, before and after implementation of an antimicrobial stewardship programme.

RESULT

There was a significant decline in the rate of toxigenic positivity from 9.8 to 7.4% following the implementation of the antimicrobial stewardship programme, and a reversal of a rising trend.

DISCUSSION

The rate of toxigenic positivity may be a useful patient outcome metric for evaluating the long-term impact of antimicrobial stewardship on CDI, especially in settings with limited surveillance resources. The accuracy of this metric is, however, dependent on the avoidance of arbitrary repeated testing of a patient for cure, and testing only unformed or diarrhoea stool specimens. Further studies are required within and beyond Saudi Arabia to examine the utility of this metric.

摘要

背景

抗菌药物管理与医疗保健相关感染(HA-CDI)发病率的降低有关。然而,在许多低收入和中等收入国家,CDI仍然未得到充分认识,这些国家往往缺乏识别HA-CDI所需的临床和监测资源。住院患者粪便中产毒粪便阳性率可能为这些环境提供一种替代指标,但其效用在很大程度上仍未得到检验。

目的

研究抗菌药物管理对腹泻住院患者中产毒阳性率的影响。

方法

对实验室数据进行了为期12年的回顾性研究,以比较沙特阿拉伯一家医院实施抗菌药物管理计划前后腹泻患者粪便中产毒情况的发生率。

结果

实施抗菌药物管理计划后,产毒阳性率从9.8%显著下降至7.4%,且上升趋势得到扭转。

讨论

产毒阳性率可能是评估抗菌药物管理对CDI长期影响的一个有用的患者结局指标,特别是在监测资源有限的环境中。然而,该指标的准确性取决于避免对患者进行随意的反复治愈检测,并且仅检测不成形或腹泻粪便标本。沙特阿拉伯国内外都需要进一步研究来检验该指标的效用。

相似文献

6
Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis.艰难梭菌:诊断与过度诊断的后果
Infect Dis Ther. 2021 Jun;10(2):687-697. doi: 10.1007/s40121-021-00417-7. Epub 2021 Mar 26.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验